Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
María Gaibar, Laura Beltrán, Alicia Romero‐Lorca, et al.
Journal of Oncology (2020) Vol. 2020, pp. 1-13
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne Robichaux, Yasir Y. Elamin, R.S.K. Vijayan, et al.
Cancer Cell (2019) Vol. 36, Iss. 4, pp. 444-457.e7
Open Access | Times Cited: 191
Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review
Agata Szymiczek, Amna Lone, Mohammad R. Akbari
Clinical Genetics (2020) Vol. 99, Iss. 5, pp. 613-637
Closed Access | Times Cited: 78
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie Wynn, Shou‐Ching Tang
Cancer and Metastasis Reviews (2022) Vol. 41, Iss. 1, pp. 193-209
Open Access | Times Cited: 50
<p>Personalized medicine in breast cancer: pharmacogenomics approaches</p>
Shabnam Jeibouei, Mohammad Esmael Akbari, Alireza Kalbasi, et al.
Pharmacogenomics and Personalized Medicine (2019) Vol. Volume 12, pp. 59-73
Open Access | Times Cited: 76
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Neil T. Conlon, Jeffrey J. Kooijman, Suzanne J.C. van Gerwen, et al.
British Journal of Cancer (2021) Vol. 124, Iss. 7, pp. 1249-1259
Open Access | Times Cited: 50
Liquid biopsy: Cell-free DNA based analysis in breast cancer
Konstantinos Venetis, Giulia Cursano, Carlo Pescia, et al.
The Journal of Liquid Biopsy (2023) Vol. 1, pp. 100002-100002
Open Access | Times Cited: 22
Six‐Membered Aromatic Nitrogen Heterocyclic Anti‐Tumor Agents: Synthesis and Applications
Jiatong Li, Ao Gu, Xiao‐Mei Nong, et al.
The Chemical Record (2023) Vol. 23, Iss. 12
Closed Access | Times Cited: 17
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
Federica Giugliano, Ambra Carnevale Schianca, Chiara Corti, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1385-1385
Open Access | Times Cited: 13
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Timothy Lewis Cannon, Michael Rothe, Pam K. Mangat, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 27, pp. 3228-3237
Closed Access | Times Cited: 5
Bifunctional carbon nanodots for highly sensitive HER2 determination based on electrochemiluminescence
Tamara Guerrero-Esteban, Cristina Gutiérrez‐Sánchez, Tania García‐Mendiola, et al.
Sensors and Actuators B Chemical (2021) Vol. 343, pp. 130096-130096
Open Access | Times Cited: 32
Molecular Testing in Breast Cancer
Lulu Sun, Ariel Wu, Gregory R. Bean, et al.
Journal of Molecular Diagnostics (2021) Vol. 23, Iss. 11, pp. 1422-1432
Open Access | Times Cited: 28
Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
Manuel Gámez-Chiachio, David Sarrió, Gema Moreno‐Bueno
Cancers (2022) Vol. 14, Iss. 18, pp. 4543-4543
Open Access | Times Cited: 19
Leveraging HER2-targeted Biparatopic Antibodies in Solid Tumors
Xinlin Liu, Xinyi Fan, Xiang Gao, et al.
Pharmacological Research (2025) Vol. 214, pp. 107687-107687
Open Access
A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells
Xinlin Liu, Linli Luan, Xi Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Advances in the study of tertiary lymphoid structures in the immunotherapy of breast cancer
Xin Li, Xu Han, Ziwei Du, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers
Charalampos Theocharopoulos, Ioannis A. Ziogas, Benedetto Mungo, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104655-104655
Closed Access
Targeting HER2 genomic alterations in non-small cell lung cancer
Jie Zeng, Weijie Ma, Richard Young, et al.
Journal of the National Cancer Center (2021) Vol. 1, Iss. 2, pp. 58-73
Open Access | Times Cited: 22
Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
Desh Deepak Singh, Hae‐Jeung Lee, Dharmendra Kumar Yadav
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 15
Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer
Yi Cao, Yunjin Li, Ruijie Liu, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2568-2568
Open Access | Times Cited: 8
HER2 mutation as an emerging target in advanced breast cancer
Giulia Bon, Francesca Sofia Di Lisa, Lorena Filomeno, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2147-2158
Open Access | Times Cited: 3
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Giovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 2, pp. 436-443
Open Access | Times Cited: 7
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Cristina Saura, Judit Matito, Mafalda Oliveira, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 21, pp. 5818-5827
Open Access | Times Cited: 17
Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer
Apolonia Novillo, Ana Fernández‐Santander, María Gaibar, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 16
Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors
Deqiang Wang, Xiaofeng Chen, Yian Du, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression
Nina Shaban, Mikhail Raevskiy, Г. С. Захарова, et al.
Biochemistry (Moscow) (2024) Vol. 89, Iss. 3, pp. 487-506
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top